
Rxsight Inc
NASDAQ:RXST

Intrinsic Value
The intrinsic value of one
RXST
stock under the Base Case scenario is
17.61
USD.
Compared to the current market price of 12.67 USD,
Rxsight Inc
is
Undervalued by 28%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Rxsight Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Rxsight Inc
Balance Sheet Decomposition
Rxsight Inc
Current Assets | 288.4m |
Cash & Short-Term Investments | 229.3m |
Receivables | 31m |
Other Current Assets | 28.1m |
Non-Current Assets | 24.6m |
PP&E | 23.5m |
Other Non-Current Assets | 1.2m |
Free Cash Flow Analysis
Rxsight Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Rxsight Inc
Revenue
|
148.3m
USD
|
Cost of Revenue
|
-41.7m
USD
|
Gross Profit
|
106.6m
USD
|
Operating Expenses
|
-143.4m
USD
|
Operating Income
|
-36.9m
USD
|
Other Expenses
|
10.3m
USD
|
Net Income
|
-26.5m
USD
|
RXST Profitability Score
Profitability Due Diligence
Rxsight Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Score
Rxsight Inc's profitability score is 30/100. The higher the profitability score, the more profitable the company is.
RXST Solvency Score
Solvency Due Diligence
Rxsight Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Score
Rxsight Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RXST Price Targets Summary
Rxsight Inc
According to Wall Street analysts, the average 1-year price target for
RXST
is 22.03 USD
with a low forecast of 16.16 USD and a high forecast of 29.4 USD.
Dividends
Current shareholder yield for RXST is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RXST
stock under the Base Case scenario is
17.61
USD.
Compared to the current market price of 12.67 USD,
Rxsight Inc
is
Undervalued by 28%.